HYPR

Company Overview — What Does Hyperfine, Inc. Do?

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut. Hyperfine, Inc. (HYPR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Maria D. Sainz and employs approximately 190 people. With a market capitalization of $107M, HYPR is one of the notable companies in the Healthcare sector.

Hyperfine, Inc. (HYPR) Stock Rating — Reduce (April 2026)

As of April 2026, Hyperfine, Inc. receives a Reduce rating with a composite score of 30.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.HYPR ranks #3,366 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Hyperfine, Inc. ranks #512 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HYPR Stock Price and 52-Week Range

Hyperfine, Inc. (HYPR) currently trades at $1.21. The 52-week high for HYPR is $2.22, which means the stock is currently trading -45.5% from its annual peak. The 52-week low is $0.53, putting the stock 127.1% above its annual trough. Recent trading volume was 383K shares, suggesting relatively thin trading activity.

Is HYPR Overvalued or Undervalued? — Valuation Analysis

Hyperfine, Inc. (HYPR) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.65x, versus the sector average of 2.75x. The price-to-sales ratio is 9.13x, compared to 1.66x for the average Healthcare stock.

At current multiples, Hyperfine, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Hyperfine, Inc. Profitability — ROE, Margins, and Quality Score

Hyperfine, Inc. (HYPR) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -97.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -72.4% versus the sector average of -33.1%.

On a margin basis, Hyperfine, Inc. reports gross margins of 49.2%, compared to 71.5% for the sector. The operating margin is -356.6% (sector: -66.1%). Net profit margin stands at -346.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -5.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HYPR Debt, Balance Sheet, and Financial Health

Hyperfine, Inc. has a debt-to-equity ratio of 35.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.34x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $22M.

HYPR has a beta of 1.70, meaning it is more volatile than the broader market — a $10,000 investment in HYPR would be expected to move 70.5% more than the S&P 500 on any given day. The stability factor score for Hyperfine, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Hyperfine, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Hyperfine, Inc. reported revenue of $12M and earnings per share (EPS) of $-0.43. Net income for the quarter was $-40M. Gross margin was 49.2%. Operating income came in at $-40M.

In FY 2025, Hyperfine, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.43. Net income for the quarter was $-36M. Gross margin was 49.8%. Revenue grew 5.2% year-over-year compared to FY 2024. Operating income came in at $-37M.

In Q3 2025, Hyperfine, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.14. Net income for the quarter was $-11M. Gross margin was 53.8%. Revenue grew -5.7% year-over-year compared to Q3 2024. Operating income came in at $-9M.

In Q2 2025, Hyperfine, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-9M. Gross margin was 49.3%. Revenue grew -25.8% year-over-year compared to Q2 2024. Operating income came in at $-10M.

Over the past 8 quarters, Hyperfine, Inc. has demonstrated a growth trajectory, with revenue expanding from $4M to $12M. Investors analyzing HYPR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HYPR Dividend Yield and Income Analysis

Hyperfine, Inc. (HYPR) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HYPR Momentum and Technical Analysis Profile

Hyperfine, Inc. (HYPR) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 44/100 reflects moderate short selling activity.

HYPR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Hyperfine, Inc. (HYPR) ranks #512 out of 838 stocks based on the Blank Capital composite score. This places HYPR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HYPR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HYPR vs S&P 500 (SPY) comparison to assess how Hyperfine, Inc. stacks up against the broader market across all factor dimensions.

HYPR Next Earnings Date

No upcoming earnings date has been announced for Hyperfine, Inc. (HYPR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HYPR? — Investment Thesis Summary

The quantitative profile for Hyperfine, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. High volatility (stability score 22/100) increases portfolio risk.

In summary, Hyperfine, Inc. (HYPR) earns a Reduce rating with a composite score of 30.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HYPR stock.

Related Resources for HYPR Investors

Explore more research and tools: HYPR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HYPR head-to-head with peers: HYPR vs AZN, HYPR vs SLGL, HYPR vs VMD.